Literature DB >> 17721626

Prothrombotic markers and early spontaneous recanalization in ST-segment elevation myocardial infarction.

Marie-Geneviève Huisse1, Emilie Lanoy, Didier Tcheche, Laurent J Feldman, Annie Bezeaud, Eduardo Anglès-Cano, Murielle Mary-Krause, Dominique de Prost, Marie-Claude Guillin, P Gabriel Steg.   

Abstract

We tested the hypothesis that selected prothrombotic biomarkers might be associated with early spontaneous coronary recanalization in patients with ST-segment elevation acute myocardial infarction (STEMI). We prospectively enrolled 123 patients with STEMI including 53 patients with spontaneous coronary recanalization (cases) and 70 patients with persistent occlusion (controls) at the time of emergent coronary angiography and before angioplasty. All had received aspirin and heparin. Blood samples were collected immediately before angioplasty to measure soluble P-selectin, circulating microparticles originating from platelets (PMPs), granulocytes (GMPs), endothelial cells (EMPs); tissue factor-associated MP (TF-MP); soluble platelet glycoprotein V (sGPV) and prothrombin F1 + 2; tissue plasminogen activator (tPA), plasminogen activator inhibitor (PAI-1) and plasmin-antiplasmin (PAP). A sub-group of 70 patients (35 cases, 35 controls) was available for flow cytometry analysis of platelet P-selectin and activated GPIIb-IIIa. Baseline clinical characteristics did not differ between groups except for more frequent hypertension and dyslipidemia in controls. Platelet activation markers and PMP did not differ between the two groups. Controls had higher numbers of EMPs and GMPs compared to cases, but the difference was no longer significant when corrected for risk factors. Controls differed from cases by higher plasma levels of sGPV [64 (47-84) ng/ml vs. 53 (44-63) ng/ml] and PAP [114(65-225) ng/ml vs. 88 (51-147) ng/ml]. The difference persisted after adjustment for risks factors (p = 0.031 and 0.037, respectively). Persistent occlusion of the infarct related artery is associated with some markers related to higher thrombin (sGPV) and plasmin (PAP) production but is not associated with markers of platelet activation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17721626      PMCID: PMC2237889     

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  46 in total

1.  Plasma glycoprotein V levels in the general population: normal distribution, associated parameters and implications for clinical studies.

Authors:  Boris Aleil; Nicolas Meyer; Valérie Wolff; Daniel Kientz; Marie-Louise Wiesel; Christian Gachet; Jean-Pierre Cazenave; François Lanza
Journal:  Thromb Haemost       Date:  2006-10       Impact factor: 5.249

2.  Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation.

Authors:  A A Belaaouaj; A Li; T C Wun; H G Welgus; S D Shapiro
Journal:  J Biol Chem       Date:  2000-09-01       Impact factor: 5.157

3.  GPV is a marker of in vivo platelet activation--study in a rat thrombosis model.

Authors:  C Ravanat; M Freund; P Mangin; D O Azorsa; C Schwartz; S Moog; S Schuhler; J Dambach; J P Cazenave; F Lanza
Journal:  Thromb Haemost       Date:  2000-02       Impact factor: 5.249

Review 4.  Procoagulant microparticles: disrupting the vascular homeostasis equation?

Authors:  Olivier Morel; Florence Toti; Bénédicte Hugel; Babé Bakouboula; Laurence Camoin-Jau; Françoise Dignat-George; Jean-Marie Freyssinet
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-09-21       Impact factor: 8.311

5.  Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects.

Authors:  Gilles Chironi; Alain Simon; Bénédicte Hugel; Muriel Del Pino; Jérôme Gariepy; Jean-Marie Freyssinet; Alain Tedgui
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-10-12       Impact factor: 8.311

6.  Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor.

Authors:  U Rauch; D Bonderman; B Bohrmann; J J Badimon; J Himber; M A Riederer; Y Nemerson
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

7.  Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy.

Authors:  H V Barron; C P Cannon; S A Murphy; E Braunwald; C M Gibson
Journal:  Circulation       Date:  2000-11-07       Impact factor: 29.690

8.  Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.

Authors:  Salim Yusuf; Shamir R Mehta; Susan Chrolavicius; Rizwan Afzal; Janice Pogue; Christopher B Granger; Andrzej Budaj; Ron J G Peters; Jean-Pierre Bassand; Lars Wallentin; Campbell Joyner; Keith A A Fox
Journal:  JAMA       Date:  2006-03-14       Impact factor: 56.272

9.  Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets.

Authors:  Hansjörg Schwertz; Neal D Tolley; Jason M Foulks; Melvin M Denis; Ben W Risenmay; Michael Buerke; Rachel E Tilley; Matthew T Rondina; Estelle M Harris; Larry W Kraiss; Nigel Mackman; Guy A Zimmerman; Andrew S Weyrich
Journal:  J Exp Med       Date:  2006-10-23       Impact factor: 14.307

10.  Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin.

Authors:  Shahrokh Falati; Qingde Liu; Peter Gross; Glenn Merrill-Skoloff; Janet Chou; Erik Vandendries; Alessandro Celi; Kevin Croce; Barbara C Furie; Bruce Furie
Journal:  J Exp Med       Date:  2003-06-02       Impact factor: 14.307

View more
  8 in total

1.  Membrane microvesicles: a circulating source for fibrinolysis, new antithrombotic messengers.

Authors:  Laurent Plawinski; Eduardo Anglés-Cano
Journal:  Haematologica       Date:  2013-07       Impact factor: 9.941

2.  Monocytic microparticles activate endothelial cells in an IL-1β-dependent manner.

Authors:  Jian-Guo Wang; Julie C Williams; Beckley K Davis; Ken Jacobson; Claire M Doerschuk; Jenny P-Y Ting; Nigel Mackman
Journal:  Blood       Date:  2011-06-23       Impact factor: 22.113

3.  Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity.

Authors:  R D Lee; D A Barcel; J C Williams; J G Wang; J C Boles; D A Manly; N S Key; N Mackman
Journal:  Thromb Res       Date:  2011-07-06       Impact factor: 3.944

Review 4.  Microparticles in hemostasis and thrombosis.

Authors:  A Phillip Owens; Nigel Mackman
Journal:  Circ Res       Date:  2011-05-13       Impact factor: 17.367

5.  The impaired fibrinolytic capacity in hypertension is unaffected by acute blood pressure lowering.

Authors:  Wilhelm Ridderstråle; Ott Saluveer; Maria Carlström; Sverker Jern; Thórdís J Hrafnkelsdóttir
Journal:  J Thromb Thrombolysis       Date:  2011-11       Impact factor: 2.300

Review 6.  Role of tissue factor in atherothrombosis.

Authors:  A Phillip Owens; Nigel Mackman
Journal:  Curr Atheroscler Rep       Date:  2012-10       Impact factor: 5.113

Review 7.  Endothelial microparticles act as novel diagnostic and therapeutic biomarkers of circulatory hypoxia-related diseases: a literature review.

Authors:  Fan Deng; Shuang Wang; Liangqing Zhang
Journal:  J Cell Mol Med       Date:  2017-03-18       Impact factor: 5.310

Review 8.  Diagnostic Impact of Radiological Findings and Extracellular Vesicles: Are We Close to Radiovesicolomics?

Authors:  Francesco Lorenzo Serafini; Paola Lanuti; Andrea Delli Pizzi; Luca Procaccini; Michela Villani; Alessio Lino Taraschi; Luca Pascucci; Erica Mincuzzi; Jacopo Izzi; Piero Chiacchiaretta; Davide Buca; Giulia Catitti; Giuseppina Bologna; Pasquale Simeone; Damiana Pieragostino; Massimo Caulo
Journal:  Biology (Basel)       Date:  2021-12-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.